NCT06006247

Early Parkinson's Disease Monotherapy With CVN424

A Randomized, Double-Blind, Placebo-Controlled Trial of CVN424 in Early Parkinson's Disease

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Cerevance Beta, Inc. · Industry
• Sex: All
• Age: 30 Years
• Healthy volunteers: Not accepted

Summary

This is a multicenter, 12-week, placebo-controlled clinical trial of CVN424 150 milligrams (mg) tablets in early, untreated Parkinson's Disease (PD). Participants will be randomized in a 1:1 ratio to CVN424 150 mg or placebo at the Baseline Visit. The purpose of this study is to measure effect on motor features with CVN424 tablets compared to placebo in early, untreated PD and to evaluate the potential of CVN424 to improve motor and non-motor functions in participants with early PD who are not taking dopaminergic or anti-PD therapies.

Conditions

• Parkinson's Disease

Interventions

Type	Name	Description
DRUG	CVN424 150 mg	Participants will receive 1 CVN424 tablet (150 mg) per day.
DRUG	Placebo	Participants will receive 1 matching placebo tablet per day.

Timeline

• Start date: 2023-09-11
• Primary completion: 2025-01-30
• Completion: 2025-02-13
• First posted: 2023-08-23
• Last updated: 2026-03-23
• Results posted: 2026-03-23

Locations

42 sites across 1 country: United States

Regulatory

• FDA-regulated drug study